ARTICLE | Clinical News
DaunoXome daunorubicin regulatory update
November 19, 2012 8:00 AM UTC
The European Commission granted Orphan Drug designation for liposomal daunorubicin to treat acute myelogenous leukemia (AML). Galen has rights from Gilead to the liposomal formulation of daunorubicin,...